SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is actively trending following its mixed earnings report, where an EPS beat and strong growth in non-crypto segments like options, subscriptions, and prediction markets are being weighed against a revenue miss driven by a significant decline in crypto transaction revenue. The community is sharply divided on whether the stock's post-earnings dip is an overreaction to the crypto drag or indicative of deeper concerns, despite the company's diversification efforts and record net deposits.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is trending after reporting better-than-expected quarterly results and robust long-term growth targets, sparking bullish enthusiasm for its AI-driven lending model while also generating community frustration over the stock's immediate, muted price action despite the positive news.

Astera Labs, Inc. is a global semiconductor company, which engages in the provision of hardware and software solutions for AI and cloud infrastructure applications to solve data, memory, and networking bottlenecks. It operates through the following geographical segments: Taiwan, China, United States, and Other. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs is trending after exceeding earnings expectations and securing a major warrant deal with Amazon for future purchases, with the community actively debating its crucial position in AI infrastructure connectivity amid its characteristic volatility.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan Green in 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is experiencing renewed investor interest following a strong Q4 earnings report, which highlighted record bookings, significant EPS growth, and a new $1 billion share repurchase program. However, community sentiment remains divided as the market continues to weigh these positive financial developments against persistent concerns regarding robotaxi competition and ongoing acquisition speculation.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending ahead of its earnings release, where a significant EV restructuring charge and outlook for 2026, especially regarding its hybrid strategy, are key discussion points. The community is split between optimism for Ford's pivot and analyst upgrades, and concerns over recent recalls and the broader challenges facing the auto sector.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration, and Cloudflare marketplace. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare (NET) is trending after reporting strong revenue and optimistic guidance that highlight its position in AI infrastructure, particularly with the Moltbot/Clawdbot buzz, although some investors are concerned about an EPS guidance miss and recent network outages.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending sharply lower following FDA restrictions on compounded GLP-1 ingredients and a patent infringement lawsuit from Novo Nordisk, which has forced the company to halt sales of its oral semaglutide pill. The community is actively debating if the stock is a falling knife headed for single digits or setting up for a massive short squeeze given its high short interest.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi is trending due to a significant stock drop following the termination of a $150 million funding agreement with a prospective tenant for its Project Matador data center campus. Despite the setback, the community is actively debating whether this presents a buying opportunity, highlighting the company's unique position to provide critical behind-the-meter power for the booming AI infrastructure demand in Texas amid ongoing tenant negotiations.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is trending as its solid Q4 performance and increased dividend are contrasted by a conservative 2026 earnings outlook, sparking community discussion on whether this presents a buying opportunity amid perceived near-term weakness.

Mattel, Inc. engages in the ownership of children's and family entertainment franchises. It operates through the following segments: North America, International, and American Girl. The North America and International segments focus on marketing and selling toys and consumer products. The American Girl segment includes marketing, retailing, and publishing dedicated to its mission to help girls grow up with confidence and character. The company was founded by Elliot Handler, Ruth Handler, and Harold Matson in 1945 and is headquartered in El Segundo, CA.

Mattel, Inc.

Mattel is trending due to a significant miss on its recent quarterly earnings and a cautious outlook, which led to a sharp stock decline that has investors debating whether it's an overreaction or a sign of deeper concerns for the toy giant.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Leerink Partners Begins Coverage on Terns Pharmaceuticals (NASDAQ:TERN)

Leerink Partners started coverage on shares of Terns Pharmaceuticals in a report on Monday. They issued an "outperform" rating and a $58.00 target price on the stock...

Wall Street Analysts See a 50.91% Upside in Terns Pharmaceuticals (TERN): Can the Stock Really Move This High?

The consensus price target hints at a 50.9% upside potential for Terns Pharmaceuticals (TERN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of "Moderate Buy" from Analysts

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has received an average recommendation of "Moderate Buy" from the thirteen brokerages that are currently covering the company...

Insider Selling: Terns Pharmaceuticals (NASDAQ:TERN) CEO Sells 68,749 Shares of Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CEO Amy Burroughs sold 68,749 shares of the firm's stock in a transaction on Thursday, January 15th. The shares were sold at an average...

Terns Pharmaceuticals (NASDAQ:TERN) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Terns Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

Insider Selling: Terns Pharmaceuticals (NASDAQ:TERN) CEO Sells $2,548,525.43 in Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CEO Amy Burroughs sold 68,749 shares of Terns Pharmaceuticals stock in a transaction that occurred on Thursday, January 15th. The shares...

<ul class="summary-bullets"><li>Viking CEO Brian Lian said at the conference earlier this week that the strategic interest in weight-loss drug deals is broader than it appears.</li><li>Lian also said in October that the company is “certainly receptive” to outside interest in its obesity program.</li><li>Novo recently lost out to Pfizer in the bidding war for smaller obesity drugmaker Metsera but completed its acquisition of Akero therapeutics in December.</li></ul>Shares of obesity drugmaker Viking Therapeutics (VKTX) rallied 17% on Wednesday after Denmark-based Wegovy producer Novo Nordisk (NVO) said it is on the lookout for merger and acquisition deals to boost its drug portfolio.Novo CEO Mike Doustdar said on Tuesday during the annual JP Morgan Healthcare conference that the company will continue searching for molecules, assets, and companies that are complementary to its portfolio.Other obesity drug manufacturing stocks also rallied at the time of writing, including Terns Pharmaceuticals (TERN), and Structure Therapeutics (GPCR). <a href="https://stocktwits.com/symbol/TERN">TERN shares</a> rose 10% at the time of writing while <a href="https://stocktwits.com/symbol/GPCR">GPCR stock</a> rose 6%.<h2 class="st-heading-2">Novo’s Recent Acquisition Attempts</h2>Doustdar said that the company can afford any amount for an asset, provided it is worth it. Talking about Novo Nordisk’s recent $10 billion bid to acquire smaller obesity drug maker Metsera, the CEO said, “We stopped at $10 billion in Metsera because to us, it was not worth a penny more.” Novo <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-ceo-eyes-big-push-towards-obesity-drug-development-in-2026/cmUafq6R4ED">lost out to Pfizer</a> in the bidding war.However, in December, Novo completed its acquisition of Akero Therapeutics for up to $5.2 billion in a bid to gain access to its experimental drug Efruxifermin, being developed for the treatment of compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH).<h2 class="st-heading-2">Viking’s Obesity Pipeline</h2>The subcutaneous formulation of Viking Therapeutics' lead candidate VK2735 is currently in late-stage trials for obesity. In a mid-stage trial, patients achieved up to 14.7% mean weight loss in 13 weeks on the drug.The company is also studying a tablet formulation of the drug.Viking CEO Brian Lian said at the conference earlier this week that the strategic interest in weight-loss drug deals is broader than it appears."I think the interest is probably broader than is visible. I think that there are more parties sort of circling around the space and very intrigued," Lian said while adding that he thinks there is a "fair amount of interest” across the industry.Lian also said in October that the company is “certainly receptive” to outside interest in its obesity program.“...having a larger party involved would be, you know, very helpful in driving the program through commercialization,” he said. “That said, I don't think it's mandatory. I think it's probably a preference, but it's not mandatory. We're prepared to go alone, but we're also prepared to engage with anybody who's interested.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around VKTX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user opined that Novo might buy Viking for about $10 billion, representing massive upside from its current near $4 billion market cap.<stembedurl>https://www.stocktwits.com/CPA_/message/641819411</stembedurl><a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> has gained 5% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-bear-says-new-fsd-subscription-model-proves-the-tech-is-not-an-asset/cmULNffR4eU">Tesla Bear Says New FSD Subscription Model Proves The Tech Is Not An Asset: Retail Echoes Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals

Novo CEO Mike Doustdar said on Tuesday during the annual JP Morgan Healthcare conference that the company will continue searching for molecules, assets and companies that are complementary to its portfolio. 

Equity

Novo CEO Mike Doustdar said on Tuesday during the annual JP Morgan Healthcare conference that the company will continue searching for molecules, assets and companies that are complementary to its portfolio. 


Terns Pharmaceuticals (NASDAQ:TERN) Trading Up 10.4% - Should You Buy?

Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Up 10.4% - Still a Buy...

Terns Pharmaceuticals (NASDAQ:TERN) Trading Down 6.3% - Here's Why

Terns Pharmaceuticals (NASDAQ:TERN) Trading Down 6.3% - Here's Why...

Terns Pharmaceuticals (NASDAQ:TERN) CEO Amy Burroughs Sells 71,339 Shares

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CEO Amy Burroughs sold 71,339 shares of the firm's stock in a transaction on Monday, January 5th. The stock was sold at an average price of...

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $SHOP earnings on Wednesday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.30	--	--	N/A
Q3 '25	-$0.30	-$0.27	9.02%	BEAT
Q2 '25	-$0.29	-$0.26	10.45%	BEAT
Q1 '25	-$0.29	-$0.26	11.54%	BEAT
Q4 '24	-$0.31	-$0.24	21.61%	BEAT

TERN
Terns Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest TERN News

TERNTerns Pharmaceuticals Inc